Ibere Pharmaceuticals Class A (IBER)
$10.18
$-0.03
(-0.29%)
As on 01-Mar-2023 15:58EDT
Market cap
$176 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
17.3
P/B Ratio
1.3
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$11 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-167.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$2.1
-
Face value
--
-
Shares outstanding
13,800,000
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ibere Pharmaceuticals Class A (IBER)
| 0.9 | 0.3 | 1.5 | 4.8 | -- | -- | -- |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
Company
|
2022
|
|---|---|
|
Ibere Pharmaceuticals Class A (IBER)
| 3.8 |
|
BSE Sensex
| 4.4 |
|
BSE Sensex
| 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ibere Pharmaceuticals Class A (IBER)
|
10.2 | 175.6 | 0.0 | 6.2 | -- | 4.7 | 17.3 | 1.3 |
| 10.1 | 295.9 | 0.0 | -7.4 | -- | -- | -- | 4.2 |
Shareholding Pattern
View DetailsAbout Ibere Pharmaceuticals Class A (IBER)
Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The... company was incorporated in 2020 and is based in Philadelphia, Pennsylvania. Read more
-
Chairman & CEO
Mr. Osagie O. Imasogie Esq.
-
CFO, Exec. VP & Director
Ms. Lisa M. Gray CPA, CPA, CVA
-
Headquarters
Philadelphia, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ibere Pharmaceuticals Class A (IBER)
What is the current share price of Ibere Pharmaceuticals Class A (IBER) Today?
The share price of Ibere Pharmaceuticals Class A (IBER) is $10.18 (NYSE) as of 01-Mar-2023 15:58 EDT. Ibere Pharmaceuticals Class A (IBER) has given a return of 4.84% in the last 1 years.
What is the current PB & PE ratio of Ibere Pharmaceuticals Class A (IBER)?
The P/E ratio of Ibere Pharmaceuticals Class A (IBER) is 17.25 times as on 01-Mar-2023.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2021 |
18.67 |
0.23 |
2020 |
-- |
-- |
2021 |
18.67 |
0.23 |
2020 |
-- |
-- |
What is the 52 Week High and Low of Ibere Pharmaceuticals Class A (IBER)?
The 52-week high and low of Ibere Pharmaceuticals Class A (IBER) are Rs -- and Rs -- as of 31-Aug-2026.
What is the market cap of Ibere Pharmaceuticals Class A (IBER)?
Ibere Pharmaceuticals Class A (IBER) has a market capitalisation of $ 176 Mln as on 01-Mar-2023. As per SEBI classification, it is a company.
Should I invest in Ibere Pharmaceuticals Class A (IBER)?
Before investing in Ibere Pharmaceuticals Class A (IBER), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.